Focal Segmental Glomerulosclerosis
📧 Sign up to get email alerts when something new happens for Focal Segmental Glomerulosclerosis.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2024-09-05FDA Approved: FILSPARI — Supplemental Application (Travere Therapeutics, Inc.)
FDA approved a supplemental application for FILSPARI (sparsentan) submitted by Travere Therapeutics, Inc., relating to changes or expansion …